Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 ...
--Preclinical Studies Demonstrate Activity of CPI-444 Both Alone and in Combination with Anti-PD-1 and Anti-PD-L1 Antibodies-- --Preliminary Phase 1/1b Clinical Biomarker Data Show Complete Blockade of Peripheral Blood Lymphocyte A2A Receptors in Dose- …